Washington University in St. Louis (WU)
My research focuses on the role of inflammatory signaling in the pathogenesis of myeloproliferative neoplasms (MPNs). Specifically, I investigate how the Galectin-1/TLR4 signaling axis drives disease-promoting inflammation in MPN and how this pathway can be therapeutically targeted. A central goal of my work is to develop lysosome-targeting chimeric antibodies (LYTACs) that redirect TLR4 to the lysosome for degradation, offering a more durable suppression of inflammatory signaling compared to conventional receptor inhibition. I employ patient-derived xenograft (PDX) models, single-cell multi-omics, and CRISPR-based approaches to dissect the mechanistic and translational dimensions of this pathway. My long-term objective is to establish a new therapeutic paradigm for targeting pathological inflammation in hematologic malignancies and to translate these findings toward novel treatment strategies for patients with MPN.